Connect with us

Technology

New England Biolabs® and Inorevia to partner on novel solutions for the preparation of challenging samples for next generation sequencing

Published

on

IPSWICH, Mass. and PARIS, June 18, 2024 /PRNewswire/ — New England Biolabs (NEB ®) and Inorevia announce a collaboration to develop automated workflows to maximize data quality by preparation of sequence-ready libraries from challenging samples using NEBNext® library preparation reagents on Inorevia’s Magelia® automation platform.

Preparing high-quality libraries for sequencing analysis from challenging samples, including those derived from formalin-fixed, paraffin-embedded (FFPE) tissue, poses several challenges to the production of high-quality sequencing data. Combining NEB’s innovative NEBNext reagents for next-generation sequencing sample preparation with Inorevia’s unique Magelia® automation platform results in workflows that improve sequencing performance by maximizing the number of molecules derived from samples that can produce accurate sequencing data.

Inorevia, with its headquarters located in the south of Paris, France, developed and manufactures its Magelia® automation platform, a unique liquid handling technology with enhanced kinetics and highly efficient magnetic bead handling, that unlocks full walk-away automation of complex workflows. New England Biolabs has been a leader in the development and manufacture of NGS sample preparation reagents for over 15 years.

“NEB is a leading company developing and manufacturing not only extremely efficient enzymes, but a large portfolio of innovative solutions for scientists around the world. Innovation is at the core of everything they do, and since our first discussions we felt our companies were a perfect match in terms of vision. This proved to be also a great fit in terms of collaboration between our teams,” comments Amel Bendali, Chief Operating Officer and co-founder at Inorevia.

NEB and Inorevia successfully collaborated on automating whole genome sequencing (WGS) library prep, including upfront fragmentation, using the NEBNext® Ultra™ II FS DNA PCR-free Library Prep Kit for Illumina® on the Magelia® platform. This first collaboration demonstrated the Magelia platform’s ability to produce high quality sequencing libraries, demonstrating a fully-automated workflow from genomic DNA at and even below the recommended input levels for the kit.

According to Fiona Stewart, Ph.D., Associate Director, NEBNext Portfolio Management at NEB, “Inorevia’s unique approach provides opportunities to enhance the performance of enzymatic reactions, driving efficiency on a molecular level, with reduced sample loss. We’re excited about the potential of combining NEB’s unique and highly optimized solutions for library preparation with the Magelia® platform to accomplish science that would otherwise be unattainable.”

About Inorevia

Co-founded in 2016, Inorevia is a French company exploiting cutting-edge patented technologies to accelerate Research in Life Sciences. Inorevia sample prep technology unlocks high resolution data, even from challenging samples, for a variety of omics applications. At the core of Inorevia’s products lie patented technologies enabling the preservation of a maximum of molecules of interest while eliminating background noise from a sample, ultimately impacting data quality. Inorevia’s highly efficient, intuitive and full walk-away instruments pave the way toward a new generation of solutions for Life Sciences. Inorevia is a privately held company headquartered in Bagneux (Paris south), France.

For more information about Inorevia, visit www.inorevia.com

About New England Biolabs

Established in the mid 1970’s, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development, as well as nucleic acid vaccines. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and subsidiaries located in Australia, Canada, China, France, Germany, Japan, New Zealand, Singapore, South Korea and the UK.

For more information about New England Biolabs visit www.neb.com.

NEB®, NEW ENGLAND BIOLABS®, and NEBNext® are registered trademarks of New England Biolabs, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-england-biolabs-and-inorevia-to-partner-on-novel-solutions-for-the-preparation-of-challenging-samples-for-next-generation-sequencing-302176013.html

SOURCE New England Biolabs, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Kong Expands with New Headquarters in Downtown San Francisco

Published

on

By

New office reinforces the company’s commitment to the Bay Area as global center of
technology innovation and top talent 

SAN FRANCISCO, May 22, 2025 /PRNewswire/ —  Kong Inc., a leading developer of cloud API technologies, today announced the expansion of its San Francisco headquarters with a new office located at 44 Montgomery Street. The move reinforces the company’s long-term investment in the Bay Area as a center of innovation and talent —and supports its mission to help every company securely adopt AI and become an API-first company. The new office accommodates 50% more employees than its previous San Francisco office and is designed to foster more collaboration, customer meetings and opportunities for employees to connect and build relationships.

“We’re excited to expand our footprint in the heart of San Francisco’s financial district. The Bay Area continues to be the center of the tech universe, and it’s important for our growth as the leading API platform company to have a significant presence here,” said Gunjan Aggarwal, Chief People Officer, Kong Inc.

Kong has seen incredible growth over the last year, having recently secured $175 million in Series E financing, bringing the company to a $2 billion valuation. The company has since invested in strategic growth, hiring, and enhancing product innovation including launching several updates to the Kong Konnect API platform, Kong AI Gateway and introducing a new Event Gateway.

Today, Kong has more than 700 employees globally in more than 25 different locations supporting 700+ businesses ranging from Fortune 500 organizations to top financial institutions and digital-first disruptors. 

Kong, a certified Great Place to Work™ company, is hiring globally and across all departments. For more information on open roles and to apply, please visit https://konghq.com/company/careers.

About Kong Inc.

Kong Inc., a leading developer of cloud API technologies, is on a mission to enable companies around the world to become “API-first” and securely accelerate AI adoption. Kong helps organizations globally — from startups to Fortune 500 enterprises — unleash developer productivity, build securely and accelerate time to market. For more information about Kong, please visit www.konghq.com or follow us on X @thekonginc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/kong-expands-with-new-headquarters-in-downtown-san-francisco-302462809.html

SOURCE Kong Inc.

Continue Reading

Technology

Phraxis Announces FDA Approval of EndoForce™ Connector for Endovascular Venous Anastomosis, Advancing Dialysis Access Innovation

Published

on

By

MINNEAPOLIS, May 22, 2025 /PRNewswire/ — Phraxis Inc., a Minneapolis-based medical device company, marks a major milestone with FDA approval of the EndoForce™ Connector for Endovascular Venous Anastomosis (EndoForce™) — a pivotal development in the evolution of dialysis access technology.

EndoForce™ is a patented endovascular implant designed to simplify and modernize the creation of arteriovenous grafts (AVGs) for hemodialysis. The device enables a unique endovascular anastomosis, eliminating the need for surgical dissection of the venous anastomosis and promoting precise, coaxial vessel-to-graft alignment. EndoForce™ is engineered to reduce tissue trauma, streamline procedural workflow, and support long-term graft performance.

John Ross, MD, lead principal investigator for the pivotal study, commented:
“I’m excited to see the EndoForce™ provide a novel anastomotic option for AVG creation. This straightforward and innovative approach enhances procedural efficiency while addressing key challenges in vascular access. Its unique design has the potential to reduce complications such as intimal hyperplasia at the graft-to-vein anastomosis, ultimately supporting improved long-term outcomes for dialysis patients.”

The device is compatible with standard 6mm ePTFE AVGs and incorporates several proprietary elements: anchoring barbs that secure the device within the vein; a flexible, ePTFE-covered nitinol segment that conforms to the graft and vessel wall; and a compressible section that expands securely within the AVG upon deployment. This configuration supports a stable, end-to-end anastomosis intended to promote laminar blood flow and reduce turbulent shear stress—factors that contribute to endothelial buildup and graft failure.

In a pivotal, multicenter, single-arm study, EndoForce™ achieved procedural success, meeting its primary endpoint of cumulative patency at six months, with a 92% patency rate. Secondary endpoints—including primary patency and technical success—further reinforced the device’s strong clinical performance.

Alexander Yevzlin, MD, CEO of Phraxis Inc., stated:
“FDA approval of the EndoForce™ Connector marks a major advancement for the dialysis community. The device introduces a new standard for AVG creation and has demonstrated exceptional ease of use and procedural reliability. While long-term outcomes are still being evaluated, we remain optimistic about its potential to improve dialysis care.”

The EndoForce™ Connector is now available to healthcare providers and clinicians, offering an innovative, minimally invasive solution for patients with end-stage renal disease (ESRD). Phraxis remains committed to supporting the successful integration of EndoForce™ into clinical practice and enabling providers to deliver improved, durable dialysis access outcomes.

About Phraxis Inc.

Based in Minneapolis, MN, Phraxis Inc. is a medical device company committed to advancing vascular access technologies for patients with end-stage renal disease (ESRD). Through innovative solutions like the EndoForce™ Connector for Endovascular Venous Anastomosis, Phraxis is focused on improving patient care by addressing critical challenges in dialysis access and delivering durable, long-term solutions for ESRD patients worldwide.

For more information:
www.phraxis.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/phraxis-announces-fda-approval-of-endoforce-connector-for-endovascular-venous-anastomosis-advancing-dialysis-access-innovation-302463380.html

SOURCE Phraxis Inc.

Continue Reading

Technology

VenturEd Solutions Launches Next-Gen SSS Platform, Revolutionizing Financial Aid Management

Published

on

By

Early users report faster processing, fewer errors, and a dramatically improved family experience.

TAMPA, Fla., May 22, 2025 /PRNewswire-PRWeb/ — VenturEd Solutions has officially launched its enhanced School and Student Services® (SSS) platform, with direct IRS integration, marking a significant advancement in financial aid processing for private and independent K–12 schools.

“This is more than a technology upgrade—this transforms financial aid processing, in a smarter and faster way for families and schools,” said Nick Laird, CEO of VenturEd Solutions.

“This is more than a technology upgrade—this transforms financial aid processing, in a smarter and faster way for families and schools,” said Nick Laird, CEO of VenturEd Solutions. “Our enhanced SSS platform breaks down barriers with an application process completed in under 9 minutes and empowers schools with the information and tools they need to serve families with transparency, security, and fairness.”

At the heart of the platform is a suite of advanced capabilities, including direct access to verified IRS tax data through a secure, built-in feature powered by TaxStatus®. Schools can now retrieve both individual and business tax records in under 60 seconds, gaining multi-year financial visibility without relying on manual uploads or outdated documentation.

Key Features and Benefits:

Frictionless Family Experience: Families can complete applications in under 9 minutes, with a single application accepted by multiple schools and no document uploads.Verified Financial Insights: Real-time access to accurate, IRS-sourced financial data across multiple years.Unmatched Data Depth: Access multi-year personal and business tax insights, digestible reports, and real-time IRS updates—all in one place.Bank Grade Security: Protecting family data with enterprise-grade encryption.Real-Time Alerts: Schools receive notifications when financial circumstances change.

Transform your Financial Aid experience and learn more at the upcoming webinar.

Early adopters of the enhanced platform are already seeing meaningful results, including faster application processing, improved administrative efficiency, and a significantly smoother process for both staff and families.

With the full rollout now underway, schools across the country can benefit from the next generation of financial aid tools.

The enhanced SSS platform puts accurate, real-time financial data at your fingertips—helping schools serve families with greater confidence and compassion.

Join the Next Era of Financial Aid Webinar – Register Now.

About VenturEd Solutions:

VenturEd Solutions is a leading solution provider exclusively dedicated to powering the success of K-12 schools, students, and families. With innovative solutions rooted in more than 50 years of service to the education sector, VenturEd Solutions empowers schools worldwide with efficient, customizable solutions that strengthen operations and drive growth. VenturEd Solutions serves over 1 million students and families at more than 28,000 schools, districts, dioceses, multi-academy trusts, and educational organizations worldwide. This comprehensive suite of solutions supports admissions and enrollment, financial aid, tuition, student information management, school payments, communications, data, and analytics to ensure schools achieve their goals and make a lasting impact in their communities. www.venturedsolutions.com

About SSS:

School and Student Services (SSS) is a trusted financial aid management solution for K-12 private and independent schools. With an intuitive, family-friendly application process and robust administrative features, SSS simplifies financial aid management, helping schools increase access, promote diversity, and support sustainable enrollment growth. Powered by NAIS’ industry-standard methodology, SSS provides schools with the tools and insights they need to make fair, consistent, and mission-aligned financial aid decisions. www.solutionsbysss.com

Media Contact:

media@venturedsolutions.com

Nettie Reynolds, Sr. Manager Media Relations

512-815-0520

Media Contact

Nettie Reynolds, VenturEd Solutions, 1 5128150520, nettie.reynolds@venturedsolutions.com, www.venturedsolutions.com

View original content to download multimedia:https://www.prweb.com/releases/ventured-solutions-launches-next-gen-sss-platform-revolutionizing-financial-aid-management-302462708.html

SOURCE VenturEd Solutions

Continue Reading

Trending